Abstract
p53 protein is a prominent tumor suppressor to induce cell cycle arrest, apoptosis and senescence, which attracts significant interest to cancer treatment. Therefore, it would be particularly important to restore the wild–type p53 that retains latent functions in the approximately 50% of tumors. MDM2 (murine double minute 2), the principal cellular antagonist of p53, has long been believed to suppress p53 activity through two main mechanisms: promoting degradation via its E3 ligase activity and masking p53 transcriptional activation by direct binding. Targeting MDM2 E3 ligase activity is becoming a potential antitumor strategy resulting from MDM2’s decisive role in controlling the fate of p53: p53 is going to degradation when entrapped into MDM2-mediated ubiquitination, where p53 can escape by abrogating MDM2 E3 ligase activity using regulators. The intensive focus on regulating MDM2 ubiquitin E3 ligase activity has led to the rapid progress of its inhibitors, which may be possible to help p53 escape from degradation and restore its function to control tumor growth. This review summarizes the current inhibitors of MDM2 E3 ligase in cancer therapy based on the understanding the regulation of MDM2 E3 ubiquitin ligase activity, including post-translational modification, interactions between MDM2 and its cofactors, and regulation of MDM2 stability.
Keywords: Antitumor strategy, degradation, E3 ligase activity, MDM2, p53, ubiquitination.
Anti-Cancer Agents in Medicinal Chemistry
Title:Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination
Volume: 16 Issue: 2
Author(s): Jinlian Wei, Yingrui Yang, Mengchen Lu, Lili Xu, Fang Liu, Zhenwei Yuan, Qichao Bao, Zhengyu Jiang, Xiaoli Xu, Xiaoke Guo, Xiaojin Zhang, Qidong You and Haopeng Sun
Affiliation:
Keywords: Antitumor strategy, degradation, E3 ligase activity, MDM2, p53, ubiquitination.
Abstract: p53 protein is a prominent tumor suppressor to induce cell cycle arrest, apoptosis and senescence, which attracts significant interest to cancer treatment. Therefore, it would be particularly important to restore the wild–type p53 that retains latent functions in the approximately 50% of tumors. MDM2 (murine double minute 2), the principal cellular antagonist of p53, has long been believed to suppress p53 activity through two main mechanisms: promoting degradation via its E3 ligase activity and masking p53 transcriptional activation by direct binding. Targeting MDM2 E3 ligase activity is becoming a potential antitumor strategy resulting from MDM2’s decisive role in controlling the fate of p53: p53 is going to degradation when entrapped into MDM2-mediated ubiquitination, where p53 can escape by abrogating MDM2 E3 ligase activity using regulators. The intensive focus on regulating MDM2 ubiquitin E3 ligase activity has led to the rapid progress of its inhibitors, which may be possible to help p53 escape from degradation and restore its function to control tumor growth. This review summarizes the current inhibitors of MDM2 E3 ligase in cancer therapy based on the understanding the regulation of MDM2 E3 ubiquitin ligase activity, including post-translational modification, interactions between MDM2 and its cofactors, and regulation of MDM2 stability.
Export Options
About this article
Cite this article as:
Wei Jinlian, Yang Yingrui, Lu Mengchen, Xu Lili, Liu Fang, Yuan Zhenwei, Bao Qichao, Jiang Zhengyu, Xu Xiaoli, Guo Xiaoke, Zhang Xiaojin, You Qidong and Sun Haopeng, Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (2) . https://dx.doi.org/10.2174/1871520615666150907093358
DOI https://dx.doi.org/10.2174/1871520615666150907093358 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Zeolitic Imidazolate Frameworks (ZIF-8) for Biomedical Applications: A Review
Current Medicinal Chemistry Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Current Pharmaceutical Design Potential Cancer Gene Therapy by Baculoviral Transduction
Current Gene Therapy Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Synthesis, Cytotoxicity and Antioxidant Activity of New Analogs of RC-121 Synthetic Derivatives of Somatostatin
Anti-Cancer Agents in Medicinal Chemistry PET Tracers Based on Zirconium-89
Current Radiopharmaceuticals Mitochondrial-Targeted Plastoquinone Derivatives. Effect on Senescence and Acute Age-Related Pathologies
Current Drug Targets Assessment and Management of the Adnexal Mass in the Pediatric Population
Current Women`s Health Reviews Seeds of Mung Bean (<i>Vigna radiata</i> (L.) R.Wilczek): Taxonomy, Phytochemistry, Medicinal Uses and Pharmacology
Current Bioactive Compounds Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Preface
Anti-Cancer Agents in Medicinal Chemistry Fundamentals of Nanocarriers and Probiotics in the Treatment of Cervical Cancer
Current Nanomedicine Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Role of Hsp70 in Cancer Growth and Survival
Protein & Peptide Letters Some Recent Synthetic Development on Compounds with Potent Activities on Hormone-sensitive Breast Cancers
Current Organic Chemistry New Antitumour Natural Products from Marine Red Algae: Covering the Period from 2003 to 2012
Mini-Reviews in Medicinal Chemistry Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
Current Radiopharmaceuticals Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Regulation of Glycolytic and Mitochondrial Metabolism by Ras
Current Pharmaceutical Biotechnology